Medicxi has closed a €500M fund, expanded its leadership team and outlined its ongoing work in drug development and company creation.
Contentlockr
Medicxi, a life sciences venture capital firm, has closed Medicxi V, a €500M fund that will support biotechnology companies built with clear product visions to transform patient care.
The oversubscribed fund drew commitments from current limited partners and several new institutional investors.
Medicxi V will operate under the firm’s asset-centric investment approach. The fund will back drug developers and founders who work on single-asset and focused biotech ventures. It will also deploy capital into companies already in the Medicxi portfolio and others that follow the firm’s asset-focused model.
Through Medicxi V, the firm aims to advance drug programs and move them toward clinical and commercial progress for patients.
Francesco De Rubertis, co-founder and Partner at Medicxi, says, “Medicxi’s longstanding success has been founded on its unique ties to leading global pharmaceutical companies and its world-class team of drug hunters and clinicians. The new €500M fund will enable Medicxi to provide the critical capital, expertise and experience to deliver transformative therapies for patients.”
Shyam Masrani promoted as new Partner
Medicxi has also announced that Shyam Masrani has been promoted to Partner. Masrani has overseen the firm’s involvement in Merus and ProfoundBio and holds board roles at Acera Therapeutics, T-CypherBio and Petalion Therapeutics.
Fund V will be handled by Francesco De Rubertis, Giovanni Mariggi, Nick Williams and Masrani.
Giovanni Mariggi, co-founder and Partner at Medicxi, says, “Medicxi’s differentiated, capital-efficient investment strategy is rapidly scaling, and we have now raised six funds in the last 10 years, totalling over €2B.”
“We are extremely grateful for the support that we have received from our existing and new limited partners, and we are excited to continue investing in cutting-edge science and accelerating the discovery of life-changing medicines for patients.”
Brief about Medicxi
Founded in 2016, Medicxi is an investment firm that works in the healthcare field. Its mission is to form and support companies that operate across the full drug development path.
The firm draws on more than two decades of work in drug development and company formation. It invests in programs at early and later points in development and supports products built with defined goals for patient needs.
Since its previous fundraise, Medicxi has built 16 companies and has recorded more than 20 clinical readouts within its portfolio. The firm has also realised over $1B through exits and listings. These outcomes include gains from Vaxcyte, Merus and Abivax, as well as the acquisitions of ViceBio by Sanofi, Versanis Bio by Eli Lilly and ProfoundBio by Genmab.
